Subset of anaplastic glioma patients benefit from adjuvant chemo

Bookmark and Share
Published: 6 Jun 2016
Views: 2083
Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Dr van den Bent talks to ecancertv at ASCO 2016 about the early results from a European phase III trial which looked at the use of adjuvant temozolomide in anaplastic glioma.

It was found that anaplastic glioma patients without 1p/19q co-deletion benefited from this.

The addition of adjuvant temozolomide also delayed disease progression by more than two years.

Read the news story or watch the press conference video for more.